D Orazio & Associates Inc. Acquires New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

D Orazio & Associates Inc. acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 11,023 shares of the company’s stock, valued at approximately $199,000.

A number of other hedge funds have also bought and sold shares of the business. New Covenant Trust Company N.A. purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $30,000. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $16.95 on Thursday. The business’s 50-day simple moving average is $17.84 and its two-hundred day simple moving average is $17.20. Teva Pharmaceutical Industries Limited has a 52 week low of $8.64 and a 52 week high of $19.31. The stock has a market cap of $19.20 billion, a PE ratio of -19.94, a P/E/G ratio of 1.34 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.